BOCA RATON, Fla., Dec. 14, 2004 (PRIMEZONE) -- Pure H20 Bio-Technologies, Inc. (Pink Sheets:PHBT) announced today it filed a new Patent Application with the United States Patent and Trademark Office, Washington, D.C. for its Iodine Water Treatment System and Method.
Joseph P. Doxey, President of Pure H20 Bio-Technologies, Inc., stated, "the invention relates to an expertly engineered halogen-disinfection water treatment system that controls the release of the disinfectant and its delivery, a method of generating safe potable drinking water."
The PHBT point-of-entry water treatment systems provide another layer of protection for individual homes, businesses and healthcare facilities in the event that municipal systems become compromised with chlorine-resistant etiological agents. Historically, the concern has been to deliver the iodine in a manner that does not present a residual in treated potable water supplies. The PHBT technology provides a new water treatment option based on a system designed with both pre-and post-absolute carbon filtration used in combination with direct crystal iodine contact for disinfection. Moreover, the PHBT system is designed not to release detectable residual halogen into the disinfected water supplies. Both the iodine concentration and the contact time can be controlled independently of pH, and have demonstrated laboratory effective kill rates to a level of log 8 against microbial agents, as recent PHBT's test results confirm.
Reminder: The CDC makes no recommendation as to the use of the portable filters on the market due to lack of independently verified results of their efficacy.
The Company
PHBT is a publicly held company specializing in the manufacturing, design and sale of its unique residential, commercial and hospital point-of-use potable water disinfection systems. These systems are specifically designed to work effectively against water-borne pathogens and remove heavy metals and objectionable biomass.
Note: The foregoing press release contains forward-looking statements that can be identified by such terminology as "expects," "potential," "suggests," "may," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed of implied by such statements. In particular, management's expectations regarding future research, development, and/or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and completion in general. Forward-looking statements speak only as to the date they were made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
For further information regarding PHBT, please visit our website at www.pureh20biotech.com